伊人直播

Table 1: unaudited sales reports: measured sales

Year	2019 voluntary scheme	Statutory scheme	Parallel imports	Total
2018 Q1	拢2,150尘	拢394尘	拢170尘	拢2,714尘
2018 Q2	拢2,191尘	拢415尘	拢182尘	拢2,787尘
2018 Q3	拢2,237尘	拢422尘	拢189尘	拢2,849尘
2018 Q4	拢2,285尘	拢425尘	拢195尘	拢2,905尘
2018	拢8,855尘	拢1,654尘	拢736尘	拢11,246尘
2019 Q1	拢2,195尘	拢411尘	拢183尘	拢2,789尘
2019 Q2	拢2,178尘	拢422尘	拢170尘	拢2,769尘
2019 Q3	拢2,304尘	拢419尘	拢165尘	拢2,888尘
2019 Q4	拢2,400尘	拢423尘	拢179尘	拢3,002尘
2019	拢9,081尘	拢1,671尘	拢697尘	拢11,449尘
2020 Q1	拢2,747尘	拢99尘	拢191尘	拢3,037尘
2020 Q2	拢2,406尘	拢95尘	拢176尘	拢2,678尘
2020 Q3	拢2,620尘	拢87尘	拢198尘	拢2,905尘

Table 1 notes

1. Table 1 sets out aggregate information about measured sales subject to the affordability mechanism. It includes information received on parallel imports and information from audited annual sales reports and unaudited quarterly sales reports provided by members of the 2019 voluntary scheme and the statutory scheme.

2. The baseline for measured sales in respect of the statutory scheme and parallel imports has been calculated in accordance with annex 4, paragraph 1 of the 2019 voluntary scheme.

3. Measured sales is defined in the glossary of the 2019 voluntary scheme for branded medicines pricing and access as 鈥渟ales of scheme products by scheme members, statutory scheme sales and parallel import sales, but excluding exemptions from measured sales鈥�.

4. Figures for the 2019 voluntary scheme reflect any audited sales reports received. Annual totals from 2019 onwards for the statutory scheme reflect any audited sales reports received.

Measured sales in any particular period reflects all relevant scheme members in either the 2019 voluntary scheme or statutory scheme during that period. For example, several companies moved from the statutory scheme to the voluntary scheme at the start of 2020. Those companies鈥� measured sales will appear under the statutory scheme in 2019 but the voluntary scheme in 2020.

Table 2: 2019 voluntary scheme sales reports: eligible sales and resulting total scheme payments

Period	Aggregate eligible sales	Resulting aggregate scheme payments
2019 Q1	拢2,069尘	拢199尘
2019 Q2	拢2,114尘	拢203尘
2019 Q3	拢2,258尘	拢217尘
2019 Q4	拢2,340尘	拢225尘
2019	拢8,785尘	拢843尘
2020 Q1	拢2,542尘	拢150尘
2020 Q2	拢2,286尘	拢135尘
2020 Q3	拢2,495尘	拢147尘

Table 2 notes

Table 2, which is derived from unaudited quarterly sales reports and any audited annual sales reports received from members of the 2019 voluntary scheme, sets out aggregate information showing eligible sales covered by the scheme payment and the resulting scheme payments.

There are 2 columns of information:

• column 1: aggregate eligible sales
• column 2: resulting aggregate scheme payments due for the respective periods

Note: eligible sales is defined in the glossary of the 2019 voluntary scheme as 鈥渟ales of scheme products but excluding exemptions from eligible sales鈥�. The percentage payment applies to these sales. Eligible sales excludes certain types of sales, including the first 拢5 million of sales by a medium-sized company and new active substance (NAS) sales. Both of these sales categories are, however, included in measured sales and, therefore, the calculation of the overall sum to be repaid across all scheme members.

Table 3: statutory scheme sales reports 鈥� net sales covered by the statutory scheme payment and resulting payments鈥�

Statutory scheme payment and resulting payments	Jan to Mar 2019	Apr to Jun 2019	Jul to Sep 2019	Oct to Dec 2019	2019
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	拢140尘	拢137尘	拢173尘	拢191尘	拢633尘
Resulting aggregate statutory scheme payment (b)	拢14尘	拢14尘	拢17尘	拢19尘	拢63尘
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	拢53尘	拢85尘	拢81尘	拢76尘	拢308尘
Resulting statutory scheme 7.8% payment (d)	拢4尘	拢7尘	拢6尘	拢6尘	拢24尘
Total resulting statutory scheme payment (b + d)	拢18尘	拢20尘	拢24尘	拢25尘	拢87尘

Statutory scheme payment and resulting payments	Jan to Mar 2020	Apr to Jun 2020	Jul to Sep 2020
Aggregate net sales covered by the applicable annual statutory scheme payment (a)	拢5尘	拢7尘	拢9尘
Resulting aggregate statutory scheme payment (b)	拢1尘	<拢1尘	<拢1尘
Net sales of extant frameworks and public contracts subject to 7.8% payment (c)	拢4尘	拢4尘	拢4尘
Resulting statutory scheme 7.8% payment (d)	<拢1尘	<拢1尘	<拢1尘
Total resulting statutory scheme payment (b + d)	拢1尘	拢1尘	拢1尘

Table 3 notes

Table 3 is derived from audited and unaudited statutory scheme sales reports. It sets out aggregate unaudited quarterly information showing net sales covered by the statutory scheme payment and the resulting payments.

General notes

Note 1: the information in all tables is that held on the Department of Health and Social Care鈥檚 database at 16 November 2020 (corrected).

Note 2: totals may not sum due to rounding.

Note 3: all tables are subject to future correction such as where audited data replaces best available data and will be updated at each quarterly publication point to reflect the latest available information. The audit and reconciliation arrangements are set out in paragraphs 4.26 to 4.31 of the 2019 voluntary scheme. The statutory scheme audit requirements are set out at paragraph 23 of the regulations.

Note 4: This document replaces the previous version which was published in December 2020. Following continual data checks, this replacement contains corrections to some of the information.